(Reuters) — Essilor International (EPA:EI), the world’s largest maker of ophthalmic lenses, said today that operating profit rose 19.6% in 2015 and forecast that revenue would grow over the coming years, helped by demand from an aging population. Operating profit rose to €1.18 billion ($1.31 billion) last year from €989 million in 2014, while revenue rose 18.4% to […]
Chinese regulators slapped a string of contact lens and eyeglass makers with more than $3 million (19 million yuan) in fines after accusing them of violating the country’s anti-trust laws.
One way to assess stock values is to compare the stock’s share price with its asset value.
The latter is the number of shares outstanding divided into total assets. When the result is compared with share prices, it can help investors decide whether a stock is over- or under-valued.
We took a look at the asset values for 15 of the world’s largest pure-play medical device companies and then compared them with the companies’ stock price.
The economic recovery has been slow going in the U.S. as the housing market and persistently high unemployment have proven particularly stubborn.
That’s why we were surprised, after looking at the employment numbers in our MassDevice Big 100 database, to find that only 3 of the largest 15 med-tech makers wound up cutting their global workforces last year.
Across the medical device industry, R&D spending in 2011 increased despite a lethargic economy, job cuts and reorganization mandates by a number of big-name companies.
Simbionix USA Corp. acquired the Arthro VR arthroscopic training simulator line from Spain’s GMV for an undisclosed amount.
The deal broadens Simbionix’s footprint in the orthopedic training arena. The Arthro VR features a line of simulated procedures using fiberglass limb replicas, 3D images and haptic sensation.
GI Dynamics (ASX:GID) has a new global commercial head in Mark Twyman, who was appointed this week alongside Robert Solomon, who will be VP of finance.
Twyman will oversee international expansion of sales and marketing efforts for the Lexington, Mass.-based obesity and Type II diabetes treatment company’s flagship EndoBarrier device.
Shares of 3M Co. (NYSE:MMM) lost nearly 6 percent today after the conglomerate reported a 1.6 percent profit slide for the third quarter and slashed its sales and earnings guidance for 2011.
3M reported profits of $1.09 billion, or $1.52 per share, on sales of $7.53 billion. That’s a top-line increase of 9.6 percent compared with Q3 2010. Wall Street analysts expected $1.61 per share for the latest quarter.